Clinical significance of regions of homozygosity detection in prenatal chromosomal microarray analysis

Ying Hao, Geng Qian, Xing‐Ping Li, Yang Jingxin, Yang Liu, Qing-Fa Huang, Yong Xu, Peining Li, Jiansheng Xie, Weiqing Wu, Bo Wu, Wenlan LiuHuman 2025 · DOI

TL;DR

This study investigates the clinical utility of detecting Regions of Homozygosity (ROH) during prenatal chromosomal microarray analysis (CMA). By analyzing over 20,000 prenatal cases, the researchers found that ROHs, while not pathogenic themselves, can flag potential autosomal-recessive disorders and uniparental disomy (UPD)-related conditions, leading to a significant additive diagnostic yield when combined with follow-up genetic testing.

What Problem Does This Paper Address?

Prenatal chromosomal microarray analysis (CMA) is a powerful tool for detecting copy-number variants (CNVs) that can cause genetic disorders. However, CMA also identifies Regions of Homozygosity (ROH) – stretches of DNA where an individual has inherited identical copies of genes from both parents. While ROHs themselves are not directly pathogenic, their presence can be a crucial indicator of underlying genetic risks. Specifically, ROHs can suggest:

  • Autosomal-Recessive (AR) Disorders: If a pathogenic variant for an AR disorder exists within an ROH, the fetus will have two copies of that variant, leading to the disorder.
  • Uniparental Disomy (UPD): This occurs when a child inherits both copies of a chromosome (or part of a chromosome) from only one parent. UPD can lead to imprinting disorders where gene expression is dependent on parental origin.

The challenge has been to systematically evaluate the clinical significance of these ROH findings in the prenatal setting and to establish the most effective follow-up strategies to translate these findings into actionable diagnoses and genetic counseling. This paper aims to fill this gap by assessing the diagnostic yield of ROH detection and subsequent investigations.

Methods

The study employed a multi-pronged approach:

  • Retrospective Case Series Analysis: The researchers reviewed data from 20,546 prenatal cases undergoing invasive genetic testing between 2015 and 2023 at a specific hospital. They identified 178 fetuses with detected ROHs.
  • Chromosomal Microarray Analysis (CMA): Standard CMA using high-resolution SNP arrays was performed to detect both CNVs and ROHs. Specific criteria were used for reporting ROHs (e.g., >10 Mb for interstitial, >5 Mb for terminal).
  • Follow-up Genetic Testing: For fetuses with ROHs, various follow-up tests were conducted, including:
  • Exome Sequencing (ES): To identify pathogenic homozygous variants within ROHs that could cause AR disorders.
  • Trio CMA: To further investigate potential UPD and identity by descent (IBD).
  • Methylation-Specific Multiplex Ligation-dependent Probe Amplification (MS-MLPA): Specifically used to detect UPD-related imprinting disorders.
  • Literature Review: The study also incorporated data from five other large Chinese prenatal case series to provide a broader context and compare findings.

Datasets

The primary dataset for this study comprised retrospective data from 178 fetuses with detected Regions of Homozygosity (ROH), identified within a larger cohort of 20,546 prenatal cases undergoing invasive genetic testing between April 2015 and December 2023.

The study also included data from five other large prenatal case series from the literature, which were used for comparative analysis of ROH detection rates, follow-up rates, and diagnostic yields.

No new benchmarks were introduced; rather, the study aimed to consolidate and analyze existing data to better understand the clinical utility of ROH detection.

Key Insights and Ideas

  • ROHs are a Significant Incidental Finding: The detection of ROHs in prenatal CMA is not rare, occurring in approximately 0.87% of cases in this study. This highlights that ROHs are a common incidental finding that warrants further investigation.
  • ROHs as a "Red Flag" for Specific Genetic Conditions: The core idea is that ROHs act as a crucial signal for two main categories of genetic conditions: autosomal-recessive disorders and uniparental disomy (UPD)-related diseases. This study provides strong evidence for this connection.
  • The Power of Integrated Genetic Testing: The study underscores the importance of a tiered approach. CMA identifies the ROH, and then targeted follow-up tests like ES and MS-MLPA are essential to uncover the underlying genetic cause.
  • Ultrasound Findings Correlate with Adverse Outcomes: While specific ultrasound findings didn't directly correlate with specific ROHs, fetuses with ROHs and ultrasound abnormalities had a significantly higher rate of adverse pregnancy outcomes (APO). This emphasizes the value of detailed ultrasound examinations in conjunction with ROH findings.
  • Consanguinity is a Key Driver of Multiple ROHs: The presence of multiple ROHs, particularly those exceeding 3% of the genome, strongly suggests parental consanguinity, which in turn increases the risk of AR disorders.

Key Results

  • ROH Detection Rate: ROHs were detected in 0.87% of the 20,546 prenatal cases analyzed.
  • Follow-up Rates: Of the 178 fetuses with ROHs, 52.8% underwent further genetic testing (ES, trio CMA, MS-MLPA).
  • Diagnostic Yield for AR Disorders: Follow-up testing identified pathogenic homozygous variants within ROHs in 2 out of 178 fetuses (approximately 1.1%), leading to a detection rate of 2.7% for AR disorders in the analyzed fetuses.
  • Diagnostic Yield for UPD-Related Diseases: Follow-up testing identified 5 fetuses with UPD-related diseases. This resulted in a detection rate of 9.6% for UPD-related diseases.
  • Overall Additive Diagnostic Yield: The combined diagnostic yield from AR disorders and UPD-related diseases, when considering the entire cohort of 20,546 prenatal cases, was 0.04%.
  • Adverse Pregnancy Outcomes (APO): The overall APO rate was 26.9%. Notably, fetuses with ROHs and ultrasound abnormalities had a higher APO rate (34.6%) compared to those without (20.2%).
  • Consanguinity Indication: Multiple ROHs (>3% of the genome) suggested parental relatedness in 8% of cases, with 79% of these confirmed to have consanguineous marriages.

Limitations and Future Work

  • Limitations:
    • Follow-up Rate: While over half of the fetuses with ROH underwent follow-up, a significant portion did not. This could be due to parental decisions, logistical challenges, or the perceived low risk. This limits the full assessment of the diagnostic potential.
  • Variability in ROH Reporting Criteria: The study acknowledges that variations in ROH reporting criteria across different laboratories can contribute to differences in detection rates.
  • Retrospective Nature: The study is retrospective, relying on existing medical records, which may have inherent limitations in data completeness or standardization.
  • Specific Cohort: The study was conducted at a single center, and while it included a large number of cases, generalizability to other populations might require further validation.
  • Future Work:
    • Standardized Reporting: The authors advocate for standardized reporting of ROHs to ensure consistency and improve interpretation.
  • Enhanced Genetic Counseling: The findings highlight the need for improved genetic counseling for parents of fetuses with ROHs, explaining the potential risks and the benefits of follow-up testing.
  • Integration of Data: Future research could focus on integrating ROH data with other prenatal screening methods (like cfDNA) and detailed ultrasound findings to refine risk assessment and diagnostic strategies.
  • Long-term Outcome Studies: While this study focuses on prenatal diagnosis, long-term follow-up of individuals diagnosed with ROH-associated conditions would be valuable.

Summary updated

Abstract

Chromosomal microarray analysis (CMA) detects pathogenic copy-number variants (pCNVs) and regions of homozygosity (ROHs) in prenatal genetic analysis. This study evaluates the clinical significance of ROH detection in prenatal settings. We reviewed 178 fetuses with ROH detected by CMA among 20,546 fetuses from 2015 to 2023. Clinical and laboratory results, including ultrasound anomalies, cell-free DNA (cfDNA) screening, karyotyping, exome sequencing (ES), and methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA), were analyzed. These 178 fetuses with ROH accounted for 0.87% of prenatal cases. Among them, 24.2% had positive cfDNA screening results, and 52.8% underwent follow-up ES, trio CMA, and MS-MLPA. Follow-up studies detected pathogenic homozygous variants within ROH in two fetuses and uniparental disomy (UPD)-related diseases in five fetuses. Our results and findings from the other five large prenatal case series from literature indicated that ROH detection in prenatal CMA has a baseline positive predictive value of 2.7% for autosomal-recessive disorders, 9.6% for UPD-related diseases, and 0.04% overall additive diagnostic yield. These findings support the use of ES and MS-MLPA for follow-up testing and provide guidance for genetic counseling in fetuses with ROH.
BibTeX
@inproceedings{hao2025clinical,
  author = {Ying Hao and Geng Qian and Xing‐Ping Li and Yang Jingxin and Yang Liu and Qing-Fa Huang and Yong Xu and Peining Li and Jiansheng Xie and Weiqing Wu and Bo Wu and Wenlan Liu},
  title = {{Clinical significance of regions of homozygosity detection in prenatal chromosomal microarray analysis}},
  booktitle = {Human},
  year = {2025},
  doi = {10.1016/j.xhgg.2025.100549},
}
Figure